New England Peptide Implements Custom Protein Production System


PepCenter© streamlines production, communication with centralized data management

GARDNER, Mass., May 1, 2008 – Researchers in drug development and vaccine discovery worldwide now can gain access to more streamlined peptide and antibody production, faster turnaround time, and increased accuracy throughout the production process, thanks to New England Peptide, LLC (NEP).

NEP’s new PepCenter© system centralizes all of the company’s customer and project data – from inquiry and sales through production and shipment. With reporting mechanisms that offer greater transparency into trends and metrics, the custom protein production system produces greater operational and process efficiencies, increases accuracy of data generation, entry and management, and further improves project turnaround time – already the industry’s fastest.

“The implementation of PepCenter is an extension of NEP’s focus on serving customers efficiently and effectively,” explains Dave Robinson, CEO. “By centralizing the information surrounding our core business, PepCenter allows us to spend time on more value-added steps for the customer while increasing data accuracy and consistency.”

PepCenter aids significantly in the retention and distribution of peptide and antibody production knowledge, says Robinson, because it is designed to fully integrate with NEP’s PepTrend© knowledge base. PepTrend, software developed by NEP, facilitates the design, synthesis, and production of synthetically made peptides by incorporating data harnessed though each peptide production run with decades worth of documented, proven peptide chemistry knowledge and trends (

With the incorporation of PepTrend into PepCenter, NEP can provide an elevated level of customer service. NEP is better positioned to advise customers of potential synthesis and purification issues that may potentially arise with their peptide sequence(s) during production, developing alternative strategies before production begins. In addition, the incorporation of PepCenter assists NEP in making real-time changes in production and delivery schedules. NEP will integrate PepCenter with its Web site later this year, says Robinson, offering customers convenient online access to order and production updates.

PepCenter also automatically generates the certificate of analysis for each peptide ordered, according to Robinson. This key quality control document includes information on raw materials, analytical data, and other production factors. PepCenter’s more comprehensive and centralized data further increases the accuracy and detail provided by NEP, already known as an industry leader for the level of detail provided for research-grade material on the certificate.

New England Peptide (, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.

Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, and HIV/AIDS. Peptides’ inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in use. All segments of the peptide market – from therapeutics and vaccines to diagnostics and cosmetics – are thriving.


Contact: Dave Robinson, New England Peptide, 978-630-0020,;_ylt=A0WTcVvDLBhIJYgAvifNybYF


"Over the past 8 years we have used NEP for synthesis of many hundreds of peptides. The quality of NEP’s product is consistently very high. The company is deeply knowledgeable in all aspects of peptide synthesis, highly collaborative, and keenly interested in meeting the changing needs of their customers with respect to scale and formatting for delivery of peptides. One example is their flash-purified product which meets the need for initial draft-level evaluation without breaking the bank. Our experience with NEP’s antibody production capabilities has also been very good..."
Steven Carr, PhD - Director of Proteomics, Broad Institute